Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
The companies will comarket Ultivue's UltiMapper assays with Leica's Bond Rx research staining platform for research applications.
The companies will integrate Fabric's Enterprise NGS data analysis, interpretation, and clinical reporting platform with Genomenon's literature search engine.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
The collaboration will make use of Fluidigm's automated microfluidic systems to accelerate the design of panels for translational and clinical researchers.
The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.
The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
The firms will comarket AATI's automated CE systems for quality control analysis of nucleic acids in Illumina's next-generation sequencing workflows.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.